The Indian Council of Medical Research (ICMR) will soon commercialise its newly developed technology synthesis of C. trachomatis heat shock protein (cHSP60) for diagnosing Chlamydia trachomatis infection in women.

The ICMR, premier medical research organisation in the country, has invited potential agencies interested in manufacturing of cHSP60 protein for diagnosing Chlamydia trachomatis infection in women to bring this antibacterial compound to next level. To ensure quality of the product, only the companies with GLP/GMP certificate will be entertained.

The proposed work of the selected agency will include cloning of PCR amplified cHSP60 gene in cloning vector -- pGEM-T easy vector; cloning in the pQE-30 expression vector; sequence confirmation; and preparing 10 mg (in two batches of 5 mg each) purified protein 90 per cent purity.

Senior officials in the ICMR said that there are several salient features to this technology developed by the National Institute of Pathology, New Delhi (an ICMR institute).

It is a serological test which helps in the diagnosis of women at higher risk of developing sequelae to C. trachomatis.  The test has potential for non- invasive identification of TFI (Tubal Factor Infertility) in infertile women, prediction of EP (Ectopic Pregnancy), indication to future abortions in spontaneous aborters and prediction of IVF (In Vitro Fertilisation) failure.

The assay is cost-effective and more sensitive than other commercially available ELISA based diagnostic assays for chlamydial cHSP60-IgG (Medac, Germany). It can be performed in field and it has a clinical relevance as it helps the gynecologist for timely therapy, thus improving the reproductive health of women.

The ICMR has filed a patent application for this technology.